Intelligence / Healthtech / New Clinical Trials / Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
27 Oct 2026: Trial registered · ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 27 Oct 2026
- Title
- ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
- Conditions
- EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07897188
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Jiangsu Aosaikang Pharmaceutical Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.